These experiments demonstrate the ability of ADO to decrease BTK phosphorylation, which is a key molecule in the B-cell receptor (BCR)-mediated signaling pathway in the B cells of healthy donors as well as HNSCC patients. This evidence concerns the gene BTK and head and neck squamous cell carcinoma.